CVM

CEL-SCI Corporation (CEL-SCI) - 10-K Summary

Business Context and Reporting Period

Company: CEL-SCI Corporation
Filing Type: Form 10-K (Annual Report)
Period Ended: September 30, 2005
Business Overview: CEL-SCI is a biotechnology company focused on developing immunotherapeutic agents. Its lead product, Multikine, is a patented mixture of cytokines designed to treat cancer, specifically advanced primary head and neck cancer. The company is preparing for a global Phase III clinical trial for Multikine, which received a "no objection" letter from Canadian regulators in August 2005. A secondary technology, L.E.A.P.S., is being tested for protection against various viral agents and bio-terrorism threats.

Key Financial Metrics (Fiscal Year 2005)

Note: Financial statements for 2004 and 2003 were restated to correct the accounting for derivative instruments and convertible debt.

Material Changes vs. Prior Period

• Revenue: Grant revenue decreased by $55,554 (17%) due to the winding down of funded grant work.
• Expenses:
  • R&D: Increased by $288,099 (15%) primarily due to costs associated with the Phase III application for Multikine.
  • G&A: Decreased by $379,736 (16%) due to reduced public relations, travel, and legal fees.
• Non-Operating Items:
  • Gain on Derivatives: Decreased significantly from $1,174,660 in 2004 to $363,028 in 2005 due to fewer outstanding derivative instruments.
  • Other Income: The company recognized $625,472 in 2005 from the settlement of a lawsuit involving former investors (CEL-SCI was not a party).
  • Interest Expense: Dropped to zero in 2005 following the conversion of remaining convertible debt in 2003.
• Liquidity: Cash balances declined by approximately $2.3 million, driven by operating losses and capital expenditures, despite financing activities.

Outlook, Risks, and Management Commentary

• Phase III Trial: Management is focused on initiating a global Phase III trial for Multikine involving approximately 500 patients. Success is critical for obtaining a Biologics License.
• Manufacturing Constraint: The company currently has no Multikine available for clinical studies as the last batch expired (2-year shelf life). Management anticipates manufacturing costs of $4 million to $5 million over 2-3 years to supply the Phase III trial.
• Capital Requirements: CEL-SCI has no product revenue and relies on equity sales, grants, and debt. It has two active equity lines of credit (Rubicon Group and Jena Holdings) totaling up to $15 million in potential funding, though the Jena line is pending SEC registration.
• Restatement & Auditors: The company restated prior years' financials due to errors in accounting for derivatives. Deloitte & Touche LLP resigned as auditors in February 2005; BDO Seidman, LLP was retained in May 2005.
• Risks: Significant risks include the inability to raise additional capital, failure of clinical trials, and the uncertainty of regulatory approval. The company has a history of operating losses and a substantial accumulated deficit of approximately $99 million.

Investor Verification Checklist

• Cash Runway: Verify if current cash ($1.96M) and available equity lines are sufficient to fund the estimated $4-5M manufacturing cost for Multikine and ongoing operations without immediate dilution.
• Phase III Protocol: Confirm the final FDA protocol approval status and the specific timeline for patient enrollment in the global trial.
• Derivative Accounting: Review the restatement details (Note 2) to understand the volatility in earnings caused by fair value adjustments of derivative instruments.
• Equity Dilution: Assess the impact of the equity lines of credit (Rubicon and Jena) and outstanding options/warrants on future share count and ownership dilution.
• Manufacturing Timeline: Monitor the schedule for the new Multikine production batches, as the lack of supply halts clinical progress.